rituximab + melphalan + prednisone + procarbazine

This is a combination regimen consisting of four drugs: - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, leading to their depletion via immune-mediated mechanisms. It is primarily used in the treatment of B-cell non-Hodgkin lymphoma and other CD20-positive hematologic malignancies. - **Melphalan** is an alkylating agent that crosslinks DNA, inhibiting DNA and RNA synthesis, resulting in cell death. It is commonly used for multiple myeloma and some lymphomas. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it induces apoptosis in certain cancer cells, especially lymphoid tissue. - **Procarbazine** is an alkylating agent that inhibits DNA, RNA, and protein synthesis by methylation of guanine residues. This specific four-drug combination does not correspond to any widely recognized or standard named regimen but represents a multi-agent chemotherapeutic approach potentially aimed at treating hematologic malignancies such as lymphoma or multiple myeloma. Each component has established use in these diseases either alone or as part of other combinations[1][3][6].